GLP‐1 receptor agonists (e.g., exenatide, liraglutide, lixisenatide, semaglutide, dulaglutide) improve insulin signaling, reduce Aβ and tau pathology, modulate MAPKs and GSK‐3β, decrease neuroinflammation, and restore cognition in Alzheimer's disease animal models, showing strong neuroprotective potential [76, 77, 78]. This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.